Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-0428
    Keywords: Type 2 diabetes ; very low-density lipoproteins ; dietary treatment
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary To evaluate possible influences of dietary intervention on the composition of very low-density lipoproteins (VLDL), ten subjects with Type 2 (non-insulin dependent) diabetes mellitus received a hypocaloric regimen. Fifteen healthy subjects served as controls. Ultracentrifuged VLDL were analysed as cholesterol, triglycerides, apolipoprotein B (apo B), and the soluble apolipoproteins C and E (polyacrylamide gel electrophoresis in urea and densitometry) before the study, after 2 weeks and then after 3 months. Compared with the control subjects, the content of cholesterol and apo E in the VLDL was elevated in the diabetic subjects, while the area ratio of apo C-II to apo C-III1 was lowered. After diet the reduction in VLDL was accompanied by compositional changes: a decrease of the cholesterol/triglyceride ratio and of the apo E/apo C area ratio. The apo C-II/apo C-III1 area ratio remained unaffected. We conclude that one beneficial effect of therapeutic intervention in diabetes may lie in lowering the level of possibly atherogenic VLDL-components.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 49 (1971), S. 437-439 
    ISSN: 1432-1440
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei Ratte, Maus, Meerschweinchen, Mensch, Kaninchen und Schwein konnte in vitro — und bei den beiden letztgenannten Species auch in vivo — eine lipolytische Wirkung eines von uns aus Schweinehypophysen dargestellten lipidmobilisierenden Polypeptids nachgewiesen werden. Beim Menschen zeigte sich nur ein Effekt auf die Glycerin-, nicht auf die Fettsäurefreisetzung; beim Schwein war in vitro keine Lipolysestimulation zu erzielen, in vivo dagegen eine starke Wirkung. Wie Untersuchungen der Cyclo-AMP-Phosphodiesterase-Aktivität im Fettgewebe des Menschen und der Ratte ergeben haben, ist als möglicher Wirkungsmechanismus eine Hemmung dieses Enzyms zu diskutieren. — Dieser Nachweis einer offenbar universellen Wirksamkeit stellt einen weiteren Hinweis auf das Vorhandensein eines speziellen lipidmobilisierenden Peptids in der Hypophyse dar.
    Notes: Summary The lipolytic effect of a polypeptide isolated from pig pituitaries was investigated in vitro and/or in vivo in 6 species. In vitro the peptide was active in the rat (MED 0,1 µg/ml), in the mouse and guinea-pig (MED 1,0 µg/ml each) and in the rabbit (MED 0,01 µg/ml). In human adipose tissue there was only an effect on glycerol liberation, in the pig no effect at all. But in vivo a strong action could be demonstrated in the minipig by injection of 100 µg/kg intravenously. Phosphodiesterase activity in adipose tissue of man and rat was inhibited by the peptide.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 52 (1974), S. 297-299 
    ISSN: 1432-1440
    Keywords: TSH ; Lipolyse ; Lipotropin ; TSH ; Lipolyse ; Lipotropin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung TSH aus Schweinehypophysen (0,5 IE/mg) reagiert mit dem Antiserum des lipidmobilisierenden Peptids A in einer identischen Präcipitationslinie. Es stimuliert die Lipolyse in vivo und in vitro im Kaninchenfettgewebe. Weiterhin wird die Lipolyseaktivität von TSH und Peptid A bei der Ratte verglichen., Peptid A selbst hat biologisch einen TSH-Gehalt unter 25 mIE/mg. Um nachzuweisen, daß im TSH eine Peptid A-Verunreinigung vorliegt, wird säulenchromatographisch eine Fraktion TSH I/2 abgetrennt, die für die Kreuzreaktion und die lipolytische Wirksamkeit beim Kaninchen verantwortlich ist.
    Notes: Summary TSH from pig pituitaries (0.5 IU/mg) reacts with the antiserum of the lipid-mobilizing peptide A with an identical precipitation line. Lipolysis is stimulated in vivo and in vitro in rabbit adipose tissue. Furthermore, lipolytic activity of TSH and peptide A in the rat is compared. Peptide A itself biologically has a TSH-content of less than 25 mIU/mg. To show that TSH has a peptide A contamination, a fraction TSH I/2 is separated by column chromatography. TSH I/2 is responsible for the cross reaction and the lipolytic effectiveness in the rabbit.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 54 (1976), S. 283-285 
    ISSN: 1432-1440
    Keywords: Type IV hyperlipoproteinemia ; biguanides ; Type IV-Hyperlipoproteinämie ; Biguanide
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 12 Patienten mit primärer Typ IV-Hyperlipoproteinämie wurde der lipidsenkende Effekt konstanter Dosen der Biguanide Metformin, Phenformin und Buformin verglichen. Nach einer zweimonatigen Diätphase hatten sich Körpergewicht, Triglyceridausgangswerte und Cholesterinplasmakonzentrationen stabilisiert. Die 3 Biguanide wurden jeweils über 2 Monate gegeben. Auf diese sechsmonatige Medikamentenperiode folgte eine weitere Diätphase. Während 0,15 g Phenformin und 2,55 g Metformin die Triglyceride um ca. 50% senkten, betrug die Senkung unter 0,30 g Buformin nur die Hälfte. Dies ist zurückzuführen auf 4 Therapieversager mit Triglyceridausgangswerten von über 700 mg/100 ml. Im Gegensatz dazu war der triglyceridsenkende Effekt der beiden anderen Biguanide umso stärker, je höher die Triglyceridausgangswerte waren. Der cholesterinsenkende Effekt der Biguanidbehandlung war weniger stark ausgeprägt. Signifikante Veränderungen des Körpergewichts sowie ein Einfluß auf Basalinsulinwerte und Glucosekonzentrationen konnten nicht beobachtet werden. Alle 3 geprüften Biguanide bewirken also in einer Dosis von jeweils 3 Tabletten eine Senkung der Triglyceride, obwohl sie in ihrer Wirksamkeit unterschiedlich und vom Grad der Type IV-Hyperlipoproteinämie abhängig sind.
    Notes: Summary In 12 patients with primary type IV hyperlipoproteinemia the lipid lowering effect of constant doses of the biguanides metformin, phenformin and buformin was compared. After a 2 months dietary period bodyweight and initial triglyceride and cholesterol plasma concentrations were stabilized. The three biguanides were given for two months each, and this 6 months drug period was followed by another dietary period. While, 0.15 g phenformin and 2.55 g metformin reduced triglycerides by about 50% the reduction by 0.30 g buformin was only half. This was due to 4 nonresponders with initial triglycerides of more than 700 mg/100 ml. In contrast the triglyceride lowering effect of the other two biguanides was positively correlated to the pretreatment triglycerides. The cholesterol lowering effect of biguanide treatment was far less pronounced. There were no significant alterations of body weight and no influence on basal insulin and glucose concentrations. In conclusion, all three biguanides tested in a dosis of 3 tablets each are effective in lowering triglycerides although differing in efficiency and depending from the degree of typ IV hyperlipoproteinemia.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 55 (1977), S. 791-794 
    ISSN: 1432-1440
    Keywords: Lipoprotein-lipids ; Clofibrate ; Type IV hyperlipoproteinaemia ; Lipoprotein-Lipide ; Clofibrat ; Typ IV-Hyperlipoproteinämie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Der Einfluß einer vierwöchigen Clofibratbehandlung auf den Triglycerid-, Cholesterin-und Phospholipidgehalt von Very Low Density Lipoproteins (VLDL), Low Density Lipoproteins (LDL) und High Density Lipoproteins (HDL) wurde bei 12 Patienten mit primärer Typ IV-Hyperlipoproteinämie untersucht. Die Senkung der Serumtriglyceride war durch einen Abfall der VLDL-Triglyceride bedingt. Darüber hinaus kam es zu einer Normalisierung der zum Teil nachweisbaren LDL-Hypertriglyceridämie. — Die Cholesterinkonzentration nahm in den VLDL und HDL, der Phospholipidgehalt nur in den VLDL signifikant ab. In den LDL änderten sich diese beiden Lipide in Abhängigkeit von ihren Ausgangswerten, die negativ mit den Serumtriglyceridkonzentrationen korrelierten. Die Normalisierung von VLDL- und LDL-Lipiden könnte mit einer beschleunigten Delipidation der Apo-B-Lipoproteine erklärt werden.
    Notes: Summary The effect of clofibrate treatment (1.5 g/day for four weeks) on triglycerides, cholesterol and phospholipids in very low density lipoproteins (VLDL), low density lipoproteins (LDL) and high density lipoproteins (HDL) was investigated in 12 patients with type IV hyperlipoproteinaemia. The decrease of serum triglycerides was due to the reduction of VLDL-triglycerides. Furthermore, LDL-hypertriglyceridemia was normalised by clofibrate. — There existed a significant decrease of VLDL- und HDL-cholesterol as well as of VLDL-phospholipids. The changes in LDL-cholesterol and LDL-phospholipids by clofibrate depended on their initial concentrations which were negatively correlated to the serum triglycerides before treatment. — The normalisation of lipid concentrations in VLDL and LDI could be explained by a stimulated delipidation of the apo B-lipoproteins.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 47 (1969), S. 1174-1175 
    ISSN: 1432-1440
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary A Lipotropin was extracted and purified by CM-Sephadex C-25 column chromatography from human pituitary glands. UV absorption spectrum and column chromatogram are in agreement with literature as well as the strong lipolytic action in vitro and in vivo in the rabbit. In human adipose tissue the fat mobilizing effect could not be demonstrated as it was in literature. Apparently there is no antigenrelationship between pig and human lipotropin.
    Notes: Zusammenfassung Aus Menschenhypophysen wurde nach dem für Schweinehypophysen angegebenen Verfahren ein Lipotropin extrahiert und durch Chromatographie auf CM-Sephadex C-25 weiter gereinigt. In Übereinstimmung mit den Angaben in der Literatur findet sich ein starker lipolytischer Effekt in vivo wie in vitro bei Kaninchen, in teilweisem Gegensatz zur Literatur jedoch nicht in vitro beim Menschen. Eine Antigenverwandtschaft zu dem aus Schweinehypophysen gewonnenen Lipotropin scheint nicht zu bestehen. UV-Absorptionsspektrum und Säulenchromatogramm sind weitgehend identisch mit entsprechenden Angaben in der Literatur.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 30 (1986), S. 191-194 
    ISSN: 1432-1041
    Keywords: colestipol ; fenofibrate ; familial hypercholesterolaemia ; lipoproteins ; serum lipids
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Effects on serum lipoproteins were studied in ten patients with familial hypercholesterolaemia (FH) during consecutive eight-week treatment periods with fenofibrate 0.3 g/day, fenofibrate plus colestipol, 15 g/day, and fenofibrate 0.25 g/day plus colestipol. VLDL, LDL, HDL, HDL2, and HDL3 were isolated by ultracentrifugation and precipitation. Lipids and apolipoproteins A–I and B were determined by enzymatic and immunonephelometric techniques, respectively. Administration of fenofibrate alone resulted in decreases in VLDL and LDL cholesterol (−48% and −18%) and in serum apolipoprotein B (−10%), but in increases in HDL, HDL2, and HDL3 (+25%, +26%, and +24%), and in serum apolipoprotein A–I (+6%). Addition of colestipol produced a further reduction in LDL cholesterol (−31%) and in serum apolipoprotein B (−19%). The effects were maintained with less fenofibrate. In FH, an acceptable therapy combines the favourable effects of sufficient lowering of LDL and of a rise in HDL.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 35 (1988), S. 579-583 
    ISSN: 1432-1041
    Keywords: simvastatin ; bezafibrate ; hypercholesterolaemia ; LCAT ; lipoproteins ; serum cholesterol ; serum triglycerides ; side-effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Sixteen subjects with familial hypercholesterolaemia were randomly assigned to treatment with simvastatin 20–40 mg/day (an inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase) or with bezafibrate 600 mg/day (a clofibrate analogue) for 12 weeks. Both drugs produced significant reductions in serum and LDL cholesterol; mean percentage fall −30.5% and −38.1% (simvastatin) and −17.8% and −20.6% (bezafibrate), respectively. Both drugs also caused a decrease in VLDL cholesterol, while only bezafibrate decreased the serum and VLDL triglyceride levels and increased HDL cholesterol and serum apolipoprotein A-I and A-II levels. Serum apolipoprotein B fell by 33.3% (simvastatin) and 15.7% (bezafibrate). Simvastatin and bezafibrate produced significant increases in the mean fractional esterification rate of LCAT, by +124,1% and +20.6%, respectively. Thus simvastatin was clearly more effective than bezafibrate in lowering LDL by enhancing its turnover, but bezafibrate had specific effects on VLDL and HDL that might be favourable in combined treatment regimens.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Journal of Chromatography B: Biomedical Sciences and Applications 225 (1981), S. 185-188 
    ISSN: 0378-4347
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Clinica Chimica Acta 124 (1982), S. 45-50 
    ISSN: 0009-8981
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Medicine
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...